Literature DB >> 21072635

Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study.

Alexandra Masson-Lecomte1, Vincent Hupertan, Eva Comperat, Christophe Vaessen, Emmanuel Chartier-Kastler, Olivier Cussenot, Marc-Olivier Bitker, Morgan Rouprêt.   

Abstract

OBJECTIVE: To assess pathological findings and oncological control afforded by radical prostatectomy (RP) in high-risk prostate cancers (PCa) at our institution.
MATERIALS AND METHODS: We performed a retrospective review of prostate cancer patients who underwent RP between 1995 and 2006 for a high-risk prostate cancer (i.e., PSA >20 or biopsy Gleason ≥8 or clinical stage ≥T2c). Biochemical recurrence was defined as a single rise in PSA levels over 0.2 ng/ml after surgery. Survival curves were elaborated by the Kaplan-Meier method and Cox proportional hazard regression analysis. For each patient, a prognostic score for recurrence was estimated, and a prediction model was then constructed.
RESULTS: Overall, 138 patients were included and followed for a median time of 53 months. Mean age at diagnosis was 63.4 years (range 39-80) and mean pre-operative PSA was 15.5 ng/ml (range 7.4-31). The median follow-up was 53 months (range 6-166). Overall, 82 patients (59%) had biochemical recurrence. The five-year PSA recurrence-free survival rate was 40%. In univariate analysis, clinically palpable tumours (T2-T3) (P = 0.032), biopsy Gleason score ≥8 (P = 0.031), seminal vesicle invasion (pT3b), positive margins and positive lymph nodes (P < 0.001) were significantly associated with recurrence. In multivariate analysis, the biopsy Gleason score ≥8, seminal vesicle invasion, positive margins and positive lymph nodes predicted recurrence (P < 0.05).
CONCLUSIONS: RP affords an acceptable oncological control at first-line treatment of selected patients with high-risk PCa. However, in certain cases, surgery alone might not be sufficient and may be part of a multimodal treatment including either adjuvant radiotherapy or androgen deprivation.

Entities:  

Mesh:

Year:  2010        PMID: 21072635     DOI: 10.1007/s00345-010-0608-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  30 in total

1.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974.

Authors:  Donald F Gleason; George T Mellinger
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

2.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

3.  Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Alan W Partin
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

4.  Changing nature of high risk patients undergoing radical prostatectomy.

Authors:  Christopher J Kane; Joseph C Presti; Christopher L Amling; William J Aronson; Martha K Terris; Stephen J Freedland
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

5.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

6.  Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Authors:  John J Coen; Anthony L Zietman; Harjot Thakral; William U Shipley
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience.

Authors:  Kien Nguyen; Stephanie Eltz; Sarah J Drouin; Eva Comperat; François Audenet; Raphaele Renard-Penna; Marc-Olivier Bitker; Emmanuel Chartier-Kastler; François Richard; Olivier Cussenot; Morgan Rouprêt
Journal:  World J Urol       Date:  2009-05-23       Impact factor: 4.226

9.  Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.

Authors:  Morgan Rouprêt; Vincent Hupertan; Eva Comperat; Sarah J Drouin; Véronique Phé; Evanguelos Xylinas; David Demanse; Mathilde Sibony; Francois Richard; Olivier Cussenot
Journal:  BJU Int       Date:  2009-02-27       Impact factor: 5.588

Review 10.  Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Authors:  S Kumar; M Shelley; C Harrison; B Coles; T J Wilt; M D Mason
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18
View more
  1 in total

1.  Prostate cancer survivorship: lifestyle changes, much needed!

Authors:  Sanchia S Goonewardene; Raj Persad; V Nanton; A Young; A Makar
Journal:  World J Urol       Date:  2014-07-10       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.